Key Highlights

  • Karyopharm Therapeutics (NASDAQ:KPTI) is quoted at USD 0.0311 before the open on November 10, 2026, a 22.25% decline from a calculated USD 0.0400, with Nasdaq trading suspended from November 11, 2026.
  • The Children's Place (NASDAQ:PLCE) fell 9.24% to USD 0.1700 after its Chapter 11 petition, with section 363 sale bids due December 9, 2026 and closing expected by late December 2026.
  • Republic Power Group (NASDAQ:RPGL) climbed 14.25% to USD 10.50 without an identified catalyst. Liminatus Pharma (NASDAQ:LIMN) advanced 9.96% to USD 2.98, also lacking a catalyst dated November 9 or 10.
  • Bluejay Diagnostics (NASDAQ:BJDX) slipped 9.24% to USD 2.26 after its 1-for-4 reverse split effective November 3, 2026, and the group's calculated market values range from roughly USD 0.7 million to USD 10.6 million.

Karyopharm Therapeutics (NASDAQ:KPTI): Down 22.25% Pre-Market Amid Chapter 11 and Delisting Notice

Karyopharm Therapeutics (NASDAQ:KPTI) is quoted at USD 0.0311 before the open on Tuesday, November 10, 2026, 22.25% under a calculated prior close of USD 0.0400. The pressure stems from the Bankruptcy process, not new Tuesday news. A prepackaged plan and a USD 55 million bankruptcy Loan came with the Chapter 11 entry on November 2, 2026, and that day the shares sank 83% to USD 0.11. A Nasdaq delisting notice followed on November 4, 2026, trading is suspended as of the open on November 11, 2026, and OTC quotes are anticipated under KPTIQ. Ayrmid leads the bidding, though no amount has been disclosed. The plan provides no distribution to common holders, and the company stated it will not contest the notice. Total Debt is listed at USD 328.53 million, and the 52-week move reads -91.51%. A published figure from October 22, 2026 lists 22.68 million shares, putting the calculated Market Value at USD 0.0311 near USD 0.7 million. Wide spreads and a total Equity loss are the particular hazards.

The Children's Place (NASDAQ:PLCE): Down 9.24% Pre-Market After Chapter 11 Petition and Section 363 Plan

The Children's Place (NASDAQ:PLCE) is quoted at USD 0.1700 before the open, 9.24% below a calculated prior close of USD 0.187. The retailer disclosed on November 9, 2026 that it filed voluntary Chapter 11 petitions in the District of New Jersey and plans to sell substantially all Assets through a section 363 process, with bids due December 9, 2026. No stalking horse bidder or Shareholder recovery estimate was given. For context, creditors get paid first in a section 363 sale, so common equity often recovers little. A published quote page listed 22.24 million shares, giving a calculated market value of about USD 3.78 million, against USD 23.35 million on October 23, 2026. The 52-week range has been USD 1.00 to USD 9.56, and trailing Revenue came to USD 1.13 billion. Stores and online channels keep operating, and a fresh term loan from current secured lenders is planned, with no size disclosed. Thin volume, wide spreads and delisting procedures are the key risks.

Republic Power Group (NASDAQ:RPGL): Up 14.25% Pre-Market, No Catalyst Found

Republic Power Group (NASDAQ:RPGL) was quoted at USD 10.50 before the open, 14.25% above a calculated prior close of USD 9.19. Nothing dated November 9 or 10, 2026 surfaced in company releases or coverage, so no catalyst can be named. Reverse splits were announced on February 19 at 1-for-20, May 26 at 1-for-40 and September 23, 2026 at 1-for-16, and the company filed to sell 15 million Class A ordinary shares. For context, a reverse split raises the quoted price without changing company value. An October 26, 2026 snapshot showed market value of USD 8.38 million on about 1.01 million shares, with Volume of 343,645 shares. At USD 10.50 that would be about USD 10.6 million (calculated). The 52-week range of USD 6.00 to USD 34,432.00 reflects split adjustment and is not meaningful. Trailing revenue was 3.64 million Singapore dollars. Dilution and a possible turn at the open are the particular dangers.

Liminatus Pharma (NASDAQ:LIMN): Up 9.96% Pre-Market, Trigger Not Identified

Liminatus Pharma (NASDAQ:LIMN) is indicated at USD 2.98 before the open, 9.96% above a calculated prior close of USD 2.71, and no catalyst dated November 9 or 10, 2026 has been located. The most recent filing is an 8-K dated November 3, 2026 covering a private Placement of 260,001 shares at USD 2.50, which would raise gross proceeds of USD 650,002.50 and is expected to close on or about November 20, 2026. The quote is 19.2% above that placement price (calculated). An October 26 snapshot put Market Capitalisation at USD 4.24 million on 1.34 million shares, with a 52-week range of USD 2.905 to USD 141.50 and volume of just 9,816 shares. The net loss of USD 12.52 million came after a 1-for-50 reverse split. A few thousand shares can shift a quote like this. Cash is missing from the published snapshot, so the funding runway cannot be confirmed. Resale Supply could dilute holders, and a turn at the open is possible.

Bluejay Diagnostics (NASDAQ:BJDX): Down 9.24% Pre-Market, No Trigger Identified

Bluejay Diagnostics (NASDAQ:BJDX) is indicated at USD 2.26 before the open, 9.24% below a calculated prior close of USD 2.49. Published coverage has no release or filing dated November 9 or 10, 2026, so nothing qualifies as a catalyst. The most recent confirmed event is a 1-for-4 reverse split effective November 3, 2026, which trimmed shares outstanding from about 4.5 million to about 1.1 million. Basic arithmetic gives a calculated market value near USD 2.5 million, and the quote works out to about USD 0.565 per pre-split share (calculated). It stands USD 1.26 above the USD 1.00 Nasdaq minimum bid (calculated). Fractional holdings are settled in cash, and the shares remain listed on The Nasdaq Capital Market. Average volume, cash, debt and the 52-week range were not verified. For context, drift lower after a reverse split is common. Dilution and possibly wide spreads are the specific risks.

Where Things Stand

Karyopharm Therapeutics (NASDAQ:KPTI) is the biggest mover at 22.25% before the open. The five names are linked by Chapter 11 filings, reverse splits or restructuring, and only two connect to a confirmed bankruptcy sale process. The lists rely on a pre-market screener snapshot from November 10, 2026. Thin names can reverse at the 9:30 a.m. ET open, as a small batch of shares may fix the price, spreads run wide and volume is a sliver of normal trading. Equity holders here face the prospect of dilution or a complete write-off, and no move should be assumed to last.